Sanjay D Goorachurn New CEO at Medisca

Sanjay D Goorachurn

Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos and Maria Zaccardo, transition into strategic advisory roles as Chair and Vice Chair, respectively. Coinciding with the company’s 35th anniversary, this decision marks a significant milestone in Medisca’s history.

In 1989, Medisca opened its doors as a team of three with two products and a vision to bridge the gaps in patient care. Today, Medisca is a global leader in personalized medicine with more than 10 locations spanning 5 countries. Powered by a workforce of over 450 employees, Medisca offers a vast portfolio of more than 2,000 product solutions to meet the needs of diverse healthcare sectors.

Don Santos Comments

“Over the course of 35 years, Medisca has seen remarkable development, grounded in its people and dynamic entrepreneurial culture. With the addition of Sanjay’s unique set of experiences and skillset, we are confident that this marks the beginning of a new chapter for Medisca.”

As a seasoned intellectual property lawyer with over 30 years of experience, Goorachurn is regarded as one of the world’s leading IP strategists working closely with senior executives of private and public companies on maximizing the commercial value of a company’s innovation and IP assets. It is Goorachurn’s distinct expertise and first-hand experience in implementing transformative growth for complex and global companies that drew Dos Santos and Zaccardo to him back in 2016, when he joined the Medisca team as a strategic advisor.

“Sanjay’s history with Medisca was an essential element that led to our decision to bring him on as our new CEO,” said Dos Santos. “Over the last 8 years, Sanjay has built authentic relationships with many Medisca people and coached us through some very successful wins, including the advancement and protection of our key innovations. It was critical to us that the company’s next CEO be someone who not only has the capability to take us forward, but also shares the same fundamental values that define who we are.”

“My goal is to preserve the entrepreneurial legacy of Tony and Maria and carry forward the company’s vision to empower personalized wellness for all,” said Goorachurn. “My focus will be centered around empowering Medisca’s people, creating a more structured infrastructure for strategic growth, building key partnerships, and continuing to leverage innovative excellence that sets Medisca apart, while expanding our global presence.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.